- Home
- NVVE vs CYCC Comparison
NVVE vs CYCC Comparison
Compare NVVE & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- CYCC
- Stock Information
- Founded
- NVVE 1996
- CYCC 1992
- Country
- NVVE United States
- CYCC Malaysia
- Employees
- NVVE 12
- CYCC N/A
- Industry
- NVVE Oil Refining/Marketing
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- CYCC Health Care
- Exchange
- NVVE Nasdaq
- CYCC Nasdaq
- Market Cap
- NVVE 7.6M
- CYCC 7.8M
- IPO Year
- NVVE N/A
- CYCC N/A
- Fundamental
- Price
- NVVE $0.47
- CYCC $7.99
- Analyst Decision
- NVVE
- CYCC
- Analyst Count
- NVVE 0
- CYCC 0
- Target Price
- NVVE N/A
- CYCC N/A
- AVG Volume (30 Days)
- NVVE 897.4K
- CYCC 227.4K
- Earning Date
- NVVE 08-14-2025
- CYCC 08-13-2025
- Dividend Yield
- NVVE N/A
- CYCC N/A
- EPS Growth
- NVVE N/A
- CYCC N/A
- EPS
- NVVE N/A
- CYCC N/A
- Revenue
- NVVE $4,949,747.00
- CYCC $10,000.00
- Revenue This Year
- NVVE $892.33
- CYCC $137.21
- Revenue Next Year
- NVVE N/A
- CYCC N/A
- P/E Ratio
- NVVE N/A
- CYCC N/A
- Revenue Growth
- NVVE N/A
- CYCC N/A
- 52 Week Low
- NVVE $0.41
- CYCC $3.08
- 52 Week High
- NVVE $8.76
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- NVVE 37.39
- CYCC 44.20
- Support Level
- NVVE $0.41
- CYCC $6.91
- Resistance Level
- NVVE $0.53
- CYCC $8.28
- Average True Range (ATR)
- NVVE 0.06
- CYCC 1.09
- MACD
- NVVE 0.01
- CYCC -0.12
- Stochastic Oscillator
- NVVE 29.81
- CYCC 29.43
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.